Issue |
BIO Web Conf.
Volume 65, 2023
EBWFF 2023 - International Scientific Conference Ecological and Biological Well-Being of Flora and Fauna (Part 2)
|
|
---|---|---|
Article Number | 05053 | |
Number of page(s) | 11 | |
Section | Preventive Healthcare and Urban Ecology | |
DOI | https://doi.org/10.1051/bioconf/20236505053 | |
Published online | 04 September 2023 |
Complex compounds of mesalazine with cyclodextrins and the prospect of their application in the ulcer disease treatment
1 Ufa University of Science and Technology”, 450076, Ufa Russia
2 Ufa Federal Research Center” of the Russian Academy of Sciences, 450054, Ufa, Russia
* Corresponding author: Borisova @email.org
Mesalazine is highly effective in the treatment of ulcerative colitis and Crohn’s disease. However, in view of the fact that this compound is easily absorbed in the upper small intestine and cannot reach the large intestine at a therapeutic concentration, it is relevant to enclose it in the cavity of cyclodextrins through the formation of inclusion complexes of the “guest–host” type. Mesalazine complexation with α-, β-, γ- cyclodextrins was studied by spectrophotometric method in aqueous solutions. We established that the composition of the resulting complexes is 1:1. In the temperature range 296 - 321 K, the stability constants are calculated, and the thermodynamic parameters of complex formation are determined. We developed a technique for the synthesis of complexes, and a prototype, and studied its antiulcer activity. The authors established that the complex of mesalazine with β- cyclodextrin has a more pronounced antiulcer activity compared to the original substances, and approximately the same action as the reference drug (Omez). However, the amount of mesalazine in the complex was only 12% wt., the remaining 88% wt. account for β- cyclodextrin. The results obtained indicate the possibility of complex formation between mesalazine and α-, β-, γ- cyclodextrins. The resulting complex compounds can become the basis of new anti-inflammatory and antiulcer drugs.
© The Authors, published by EDP Sciences, 2023
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.